Antibodies to reverse transcriptase in HIV infection and progression to AIDS
Serum antibodies to the reverse transcriptase (ART) of human immunodeficiency virus 1 (HIV-1) were sequentially determined by ELISA in a group of 41 HIV-seropositive male homosexuals and 101 matched healthy controls, over 1.5-6 years (mean follow-up 3.25 years). Mean ART levels were significantly higher in the patient group as compared to the controls (195 +/- 75 vs. 75 +/- 45 absorbance (A) units; P less than 0.05). When analyzed in parallel with clinical evaluation and T-cell subset determinations, a "surge" in ART activity was associated with a more favourable course: eleven patients whose ART profile showed an increase greater than 100 A units (mean delta A 159.6 units) showed an attenuated decrease of CD4+ (T helper) lymphocytes with a mean time of 42.5 months to reach a CD4+ number of 400 cells/mm3. In contrast, 25 matched seropositive patients whose ART remained constant became CD4+ less than 400 cells/mm3 within a mean time of 10.8 months (P less than 0.05). These results as well as individual patients' data support a surge in serum ART as a favourable prognostic indicator, and may indicate a protective role for this antibody which should be followed up and possibly utilized in the treatment or in the design of a vaccine against HIV-1.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1992 |
---|---|
Erschienen: |
1992 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Immunology letters - 33(1992), 2 vom: 16. Juli, Seite 207-10 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Schattner, A [VerfasserIn] |
---|
Themen: |
EC 2.7.7.49 |
---|
Anmerkungen: |
Date Completed 30.12.1992 Date Revised 24.08.2019 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM01260397X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM01260397X | ||
003 | DE-627 | ||
005 | 20231221053041.0 | ||
007 | tu | ||
008 | 231221s1992 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0042.xml |
035 | |a (DE-627)NLM01260397X | ||
035 | |a (NLM)1280249 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Schattner, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antibodies to reverse transcriptase in HIV infection and progression to AIDS |
264 | 1 | |c 1992 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 30.12.1992 | ||
500 | |a Date Revised 24.08.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Serum antibodies to the reverse transcriptase (ART) of human immunodeficiency virus 1 (HIV-1) were sequentially determined by ELISA in a group of 41 HIV-seropositive male homosexuals and 101 matched healthy controls, over 1.5-6 years (mean follow-up 3.25 years). Mean ART levels were significantly higher in the patient group as compared to the controls (195 +/- 75 vs. 75 +/- 45 absorbance (A) units; P less than 0.05). When analyzed in parallel with clinical evaluation and T-cell subset determinations, a "surge" in ART activity was associated with a more favourable course: eleven patients whose ART profile showed an increase greater than 100 A units (mean delta A 159.6 units) showed an attenuated decrease of CD4+ (T helper) lymphocytes with a mean time of 42.5 months to reach a CD4+ number of 400 cells/mm3. In contrast, 25 matched seropositive patients whose ART remained constant became CD4+ less than 400 cells/mm3 within a mean time of 10.8 months (P less than 0.05). These results as well as individual patients' data support a surge in serum ART as a favourable prognostic indicator, and may indicate a protective role for this antibody which should be followed up and possibly utilized in the treatment or in the design of a vaccine against HIV-1 | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a HIV Antibodies |2 NLM | |
650 | 7 | |a HIV Reverse Transcriptase |2 NLM | |
650 | 7 | |a EC 2.7.7.49 |2 NLM | |
650 | 7 | |a RNA-Directed DNA Polymerase |2 NLM | |
650 | 7 | |a EC 2.7.7.49 |2 NLM | |
700 | 1 | |a Milchan, R |e verfasserin |4 aut | |
700 | 1 | |a Kaminchik, J |e verfasserin |4 aut | |
700 | 1 | |a Yavin, Z |e verfasserin |4 aut | |
700 | 1 | |a Bentwich, Z |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Immunology letters |d 1983 |g 33(1992), 2 vom: 16. Juli, Seite 207-10 |w (DE-627)NLM012603953 |x 1879-0542 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:1992 |g number:2 |g day:16 |g month:07 |g pages:207-10 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 1992 |e 2 |b 16 |c 07 |h 207-10 |